CORONA Remedies Expands With Wokadine® Acquisition From Dr. Reddy’s

CORONA Remedies Limited, headquartered in Ahmedabad, revealed the acquisition on March 30, 2026. The move underscores its strategy of deepening market penetration and expanding its therapeutic portfolio, particularly in women’s healthcare, cardio-diabetes, pain management, and urology.  

Strategic Expansion Into Povidone Iodine Market  
The acquisition of Wokadine®, ranked #2 in India’s Povidone Iodine segment, allows CORONA Remedies to leverage a 46-year legacy of trust among surgeons, ENT specialists, general physicians, and gynecologists. With 14 SKUs, Wokadine® offers diverse applications for clinicians treating patients across urban and rural India.  

Strengthening Distribution And Growth Potential  
CORONA Remedies plans to integrate Wokadine® into its extensive pan-India distribution network, ensuring wider accessibility. The acquisition is fully funded through internal accruals and cash, reflecting the company’s strong financial position.  

Key Highlights 

• CORONA Remedies acquires Wokadine® from Dr. Reddy’s  
• Fifth acquisition by CORONA Remedies  
• Entry into INR 648 crore Povidone Iodine market  
• 14 SKUs with varied clinical applications  
• Fully funded via internal accruals and cash  

Sources: CORONA Remedies Limited press release